Literature DB >> 6962539

Pharmacological properties of colloidal bismuth subcitrate (CBS, DE-NOL).

J Wieriks, W Hespe, K D Jaitly, P H Koekkoek, U Lavy.   

Abstract

In pharmacological ulcer models in rats colloidal bismuth subcitrate (CBS) demonstrated anti-ulcer activity. This was neither a result of an acid neutralizing nor of an acid secretion inhibitory effect. Both in vitro and in vivo, an anti-peptic action was found. At low pH CBS precipitates and was shown to form a coating on the gastric wall especially on the ulcer crater. This coating most likely forms a protective barrier to the peptic activity of gastric juice. Low toxicity was seen following chronic daily administration of high doses of CBS for 3 months to rats and 6 months to dogs. Although the blood levels were more elevated in rats, the tissue bismuth levels were comparable in the two species (except for the caecum). The chief bismuth-excreting organs, the kidneys, showed relatively high concentrations, while the brain-concentrations were extremely low in concordance with the absence of nervous system toxicity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6962539

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  13 in total

Review 1.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Effect of bismuth subcitrate on amphibian gastroduodenal bicarbonate secretion.

Authors:  C J Shorrock; J R Crampton; L C Gibbons; W D Rees
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

4.  Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol).

Authors:  J H Baron; J Barr; J Batten; R Sidebotham; J Spencer
Journal:  Gut       Date:  1986-05       Impact factor: 23.059

5.  Pathogenetic role of Helicobacter pylori in duodenal ulcer disease. Multivariate analysis of factors affecting relapse.

Authors:  W M Hui; J Ho; S K Lam
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

Review 6.  Mucosal coating agents and other nonantisecretory agents. Are they cytoprotective?

Authors:  P H Guth
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

7.  Chemical structure of bismuth compounds determines their gastric ulcer healing efficacy and anti-Helicobacter pylori activity.

Authors:  G S Sandha; R LeBlanc; S J Van Zanten; T D Sitland; L Agocs; N Burford; L Best; D Mahoney; P Hoffman; D J Leddin
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

8.  Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins.

Authors:  S J Konturek; T Radecki; I Piastucki; T Brzozowski; D Drozdowicz
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

9.  Colloidal bismuth subcitrate-induced changes on gastric mucosal hemodynamics in the rat: gastric mucosal blood flow after CBS treatment.

Authors:  E Eleftheriadis; K Kotzampassi; E Tzartinoglou; A Salem; H Aletras
Journal:  Gastroenterol Jpn       Date:  1991-06

10.  Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.

Authors:  D J Muñoz; C Tasman-Jones; J Pybus
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.